Baidu
map

Clin Chem:在苏氨酸71位未发生糖基化的ProBNP在心力衰竭患者中的特点?

2019-10-19 gladiator MedSci原创

心衰竭(HF)是全世界发病率和死亡率的主要原因。血浆b型利钠肽(BNP)或其氨基末端同源物(NT-proBNP)的浓度可用于HF的诊断和风险分层。由于肥胖患者BNP浓度异常降低,我们研究了心力衰竭患者的proBNP糖基化、血浆NT-proBNP和体重指数(BMI)之间的关系。

心衰(HF)是全世界发病率和死亡率的主要原因。血浆b型利钠肽(BNP)或其氨基末端同源物(NT-proBNP)的浓度可用于HF诊断和风险分层。由于肥胖患者BNP浓度异常降低,我们研究了心力衰竭患者的proBNP糖基化、血浆NT-proBNP和体重指数(BMI)之间的关系。

建立了三种测定方法来区分总proBNP(糖基化+非糖基化proBNP)、未在苏氨酸71位点糖基化的proBNP (NG-T71)和未在中心区域糖基化的proBNP (NG-C)。实验内和实验间CVs <15%;检出限<21 ng/L;并将样品平行稀释。

研究人员应用这些分析和NT-proBNP的测定以血浆样品从106名健康志愿者和238HF患者中确定proBNP水平,NG-T71,和NT-proBNP的浓度[中位数(四分位数间距)],与对照组相比,心衰患者NT-proBNP更大[分别为300(44 664)114(18 254)179 (880 3459)ng/L vs 36(18 229)36(18 175)40 (17 68)ng/L;P < 0.012]。在大多数样品中检测不到NG-CHF患者proBNP浓度与BMI没有差异(P = 0.85)。与BMI <30 kg/m2患者相比,而BMI>30 kg/m2 HF患者与NT-proBNPNG-T71浓度(P <0.003)较低,但proBNP/NT-proBNPproBNP/NG-T71 比率(P = 0.001 and P = 0.02, 分别较高

研究表明,BMI增加与T71时未糖基化的proBNP浓度降低有关。proBNP底物的降低可以在部分解释在肥胖个体(包括HF患者)中观察到的NT-proBNPBNP浓度的降低。

原始出处:

Lynley K. Lewis, Sara D. Raudsepp,ProBNP That Is Not Glycosylated at Threonine 71 Is Decreased with Obesity in Patients with Heart Failure

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1289333, encodeId=646c128933338, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Mon Oct 21 09:58:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318311, encodeId=9b8613183114f, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Mon Oct 21 09:58:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602202, encodeId=4f3a16022024d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Oct 21 09:58:00 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
    2019-10-21 huiwelcome
  2. [GetPortalCommentsPageByObjectIdResponse(id=1289333, encodeId=646c128933338, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Mon Oct 21 09:58:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318311, encodeId=9b8613183114f, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Mon Oct 21 09:58:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602202, encodeId=4f3a16022024d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Oct 21 09:58:00 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
    2019-10-21 lfyang
  3. [GetPortalCommentsPageByObjectIdResponse(id=1289333, encodeId=646c128933338, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Mon Oct 21 09:58:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318311, encodeId=9b8613183114f, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Mon Oct 21 09:58:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602202, encodeId=4f3a16022024d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Oct 21 09:58:00 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
    2019-10-21 sunylz

相关资讯

Heart:无房扑/房颤的心力衰竭患者与缺血性卒中的相关性

由此可见,即使没有AF或AFL,HF仍是IS的重要独立危险因素。临床医生应通过常规筛查和仔细监测HF患者来调查IS。

阿斯利康的SGLT2抑制剂达格列嗪治疗心力衰竭获得FDA的快速通道认证

阿斯利康宣布,美国食品和药物管理局为其每日口服一次的SGLT2抑制剂Farxiga(达格列嗪)授予快速通道认证,以降低射血分数保留的心力衰竭(HFpEF)和射血分数下降的心力衰竭(HFrEF的)心血管(CV)死亡风险或恶化分数。阿斯利康生物制药研发部门负责人Mene Pangalos评论说:"我们期待与FDA合作,探索Farxiga作为心力衰竭患者的潜在新治疗方案。"

JACC-Heart Failure:未矫正先天性心脏病孕妇的心力衰竭和死亡率

由此可见,该研究的结果表明未经矫正的CHD与矫正后的CHD孕妇心脏状况存在显著差异,结局明显更差,特别是在患有艾森曼格综合征和来自新兴国家的女性。

2019 ACC专家共识决策路径:心力衰竭住院患者的风险评估,管理和临床路径

2019年9月,美国心脏病学会(ACC)发布了心力衰竭住院患者的风险评估,管理和临床路径共识。文章主要由5个节点构成:入院,检查路径,口服药物治疗,出院,首次随访。

Stroke:缺血性卒中患者心力衰竭的影响

由此可见,在这个现实的卒中患者队列中,HF是功能性长期预后不良的独立预测因子,而患者静脉溶栓和机械再通的安全性和有效性似乎未受到影响。

Circ-Heart Fail:左心室辅助装置应用中的性别差异

女性约占晚期心力衰竭人群的三分之一,但接受治疗的仅占少数,包括左心室辅助装置(LVADs)。在早期脉动流装置期,女性植入LVAD后死亡率更高,并发症增加。然而,关于连续流装置期差异的认识有限。因此,Aditya A. Joshi等研究者试图探讨按性别划分的LVAD使用率和LVAD后死亡率的时间趋势。

Baidu
map
Baidu
map
Baidu
map